BALTIMORE, Nov. 26, 2018 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today announced that preclinical data demonstrating MILs’ potential as a robust platform for chimeric-antigen receptor (CAR)-modified T cell therapy have been selected for a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting, to be held December 1-4, 2018, in San Diego, CA.
MILs are a population of polyclonal T cells derived from the bone marrow that are enriched with memory T cells and contain tumor antigen-specific T cells that are typically not detected in peripheral blood lymphocytes (PBLs). MILs are being developed for several tumor types, including both hematological and solid tumors.
“We believe that MILs may be the preferred cell product for any number of cell therapy applications, including those featuring gene modifications. We look forward to presenting preclinical data at ASH that suggest MILs may offer a compelling new platform for CAR T therapy,” said Brian Halak, PhD, President and CEO of WindMIL Therapeutics. “These data suggest that CAR-modified MILs (MIL CARs) may provide both better antigen specific killing and, more importantly, prevent or minimize the risk of relapse via antigen escape variants by targeting the endogenous antigenic repertoire, thereby increasing the overall efficacy of CAR adoptive T cell therapy.”
Details of the poster presentation are as follows:
| Title: Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy | |||
| Abstract Number: 3337 | |||
| Session: 703. Adoptive Immunotherapy: Poster II | |||
| Date and Time: Sunday, December 2, 2018; 6:00 – 8:00 p.m. PT | |||
| Location: San Diego Convention Center, Hall GH | |||
| Presenter: Eric R. Lutz, PhD, WindMIL Therapeutics, Baltimore, MD |
The abstract can be viewed online through the ASH meeting website at www.hematology.org.
About WindMIL Therapeutics
WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow infiltrating lymphocytes (MILs™) for cancer immunotherapy. As the leader in cellular therapeutics emanating from bone marrow, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients. The company’s proprietary process to extract, activate and expand these cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential, and long persistence. For more information, please visit: https://windmiltherapeutics.com.
Media Contact:
Tony Plohoros
6 Degrees
(908) 940-0135
tplohoros@6degreespr.com